IPO - Aspargo Laboratories, Inc.

Form Type: S-1

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000175392625000065

Filing Summary: Aspargo Labs, Inc. filed a registration statement under the Securities Act of 1933 to register the resale of up to 176,986,993 shares of its common stock. This document serves as a prospectus for stockholders intending to sell their shares and indicates that currently no public market exists for the company’s common stock. The company's first product is Sildenafil Oral Suspension, approved for sale in several European countries and under approval in the United States. The company is positioned as an emerging growth and smaller reporting company and highlights significant plans for public trading on the NYSE under the symbol 'AAGO'. Details regarding its business focus, innovative drug delivery systems, and marketing strategies through its proprietary liquid medication formulations are emphasized. The company's mission centers around improving patient outcomes via medication adherence through the modernized liquid dosage forms and electronic drug delivery devices.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000175392625000076

Filing Summary: Aspargo Labs, Inc. is filing this Registration Statement on Form S-1/A to register the resale of up to 176,986,993 shares of its common stock. The document outlines the company's mission to enhance patient outcomes through proprietary oral liquid suspension formulations that are electronically assisted for improved medication adherence. The initial commercial product is Sildenafil Oral Suspension, which aims to provide a better alternative to traditional solid medications. Aspargo has already obtained marketing authorizations in several countries and intends to commence trading on the NYSE under the symbol 'AAGO.' The document highlights their emerging growth company status and discusses their business strategies and risk factors associated with the IPO. Currently, there is no public trading of the company's shares, and the opening price will be determined based on market conditions prior to the commencement of trading.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-09-13

Corporate Action: Ipo

Type: New

Accession Number: 000175392624001573

Filing Summary: Aspargo Laboratories, Inc. has confidentially submitted an amendment to its draft registration statement under the SEC for an Initial Public Offering (IPO) in the form of a DRS/A on September 13, 2024. This statement outlines their business strategy which focuses on developing proprietary oral liquid suspension formulations of common medications. The company addresses the limitations of traditional tablet forms, especially for patients facing dysphagia. Their primary product, Sildenafil Oral Suspension, aims to improve patient adherence through a digitally connected drug delivery system. The company is identified as an emerging growth business and a smaller reporting company, thus enabling reduced reporting requirements. The prospectus describes the risks associated with investing in the stock and the company's future financial performance. Aspargo Labs is seeking to list its shares on the NYSE, emphasizing the lack of a current public market for its securities, and predominantly relies on shareholder resale without underwriters.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-08-07

Corporate Action: Ipo

Type: New

Accession Number: 000175392624001378

Filing Summary: Aspargo Laboratories, Inc. has confidentially submitted a draft registration statement for an initial public offering (IPO) under Form S-1 on August 7, 2024. The company, which specializes in developing proprietary oral liquid suspension formulations, particularly Sildenafil Oral Suspension, aims to improve medication adherence through innovative drug delivery systems. The registration statement describes the company as a smaller reporting and emerging growth company. Aspargo intends to list its common stock on the New York Stock Exchange. The prospectus outlines risks, its business model, product offerings, and its core strategies, targeting improvements in patient medication compliance through digital innovations and liquid dosing solutions.

Document Link: View Document

Form Type: DRS

Filing Date: 2024-05-14

Corporate Action: Ipo

Type: New

Accession Number: 000175392624000961

Filing Summary: Aspargo Laboratories, Inc. filed a confidential draft registration statement on Form S-1 with the SEC as of May 14, 2024, indicating plans for an initial public offering (IPO). The company is a commercial stage specialty pharmaceutical and med-tech firm focused on developing proprietary oral liquid suspension formulations for medications, particularly targeting issues faced by patients with traditional solid dosage forms. Their first product, Sildenafil Oral Suspension, has been developed to improve dosing adherence and user experience. Aspargo Labs intends to introduce their common stock for trading on the NYSE, reflecting their strategy to enhance medication delivery with a digitally connected device designed for real-time dosing data. The document highlights their innovative approach and the drawbacks of conventional tablets, advocating for the benefits of liquid dosage forms as an effective solution for diverse patient needs. The prospectus suggests that the company has registered its trademarks and acquired relevant regulatory approval for their products, while also outlining the potential market and financial factors relevant to this offering.

Document Link: View Document